Intercept Pharma (ICPT) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RBC Comments on Intercept Pharmaceuticals (ICPT) Ahead of Competitor Data
March 2, 2015 3:51 PM ESTRBC Capital maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Analyst Michael J. Yee thinks the stock can go up even if competitor GenFit reports positive data in March.
"We think risk/reward is skewed to upside into GenFit data H2 of March because if GenFit isn't clean data then ICPT could go up 20% or more, and if... More
Intercept Pharmaceuticals (ICPT) PT Adjusted to $300 at Janney Capital; Bullish Into 2015 Catalysts
March 2, 2015 1:06 PM ESTJanney Capital analyst Chiara Russo reiterated a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) following Q4 results while updating her price target to $300.00 (from $311.00). The firm said 2015 will bring big catalysts for the stock.
"After posting a wider than expected loss on 4Q14 and... More
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Summer Street Posts Q4
March 2, 2015 8:34 AM ESTSummer Street analyst Jim Molloy reiterated a Buy rating and $650 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the company reported Q4 results and still sees 2015 adj. oper expenses $180m-$200 millino.
Molloy comments, "ICPT is presenting new subgroup analyses from Phase IIb Flint trial of obeticholic acid (OCA) in (NASH) at poster session at American... More
